Healthcare [ 10/13 ] | Biotechnology [ 90/160 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 15, 23 | -0.82 Decreased by -1.26 K% | -0.04 Decreased by -1.95 K% |
| Aug 14, 23 | -0.68 Decreased by -1.04 K% | -0.06 Decreased by -1.04 K% |
| May 15, 23 | -0.06 Increased by +70% | -0.05 Decreased by -20% |
| Mar 31, 23 | -0.15 Increased by +51.61% | -0.15 |
| Oct 14, 22 | -0.06 Increased by +14.29% | -0.12 Increased by +50% |
| Aug 15, 22 | -0.06 Increased by +25% | -0.12 Increased by +50% |
| May 16, 22 | -0.2 Decreased by -300% | -0.2 |
| Mar 31, 22 | -0.31 Decreased by -29.17% | -0.04 Decreased by -675% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 15.88 K Decreased by -62.42% | -3.32 M Increased by +12.15% | Decreased by -20.89 K% Decreased by -133.77% |
| Jun 30, 23 | 6.11 K Decreased by -98.05% | -2.26 M Decreased by -16.24% | Decreased by -37.05 K% Decreased by -5.85 K% |
| Mar 31, 23 | 128.27 K Increased by +399.89% | -73.53 K Increased by +98.79% | Decreased by -57.33% Increased by +99.76% |
| Dec 31, 22 | 588.99 K Increased by +1.66 K% | -4.5 M Increased by +43.26% | Decreased by -764.17% Decreased by -103.64% |
| Sep 30, 22 | 42.27 K Decreased by -57.3% | -3.78 M Decreased by -109.05% | Decreased by -8.93 K% Decreased by -389.63% |
| Jun 30, 22 | 312.86 K Increased by +895.07% | -1.95 M Increased by +1.23% | Decreased by -622.43% Increased by +90.07% |
| Mar 31, 22 | 25.66 K Decreased by -90.25% | -6.09 M Decreased by -439.44% | Decreased by -23.72 K% Decreased by -5.43 K% |
| Dec 31, 21 | -37.79 K Decreased by -160.77% | -7.93 M Decreased by -63.61% | Increased by +20.99 K% Increased by +369.24% |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.